Amylyx Pharmaceuticals (AMLX) Revenue & Revenue Breakdown
Amylyx Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$87.37M
Amylyx Pharmaceuticals Revenue by Period
Amylyx Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $87.37M | -77.06% |
2023-12-31 | $380.79M | 1612.94% |
2022-12-31 | $22.23M | 7700.00% |
2021-12-31 | $285.00K | -56.15% |
2020-12-31 | $650.00K | -54.42% |
2019-12-31 | $1.43M | - |
Amylyx Pharmaceuticals generated $87.37M in revenue during NA 2024, up -77.06% compared to the previous quarter, and up 6127.00% compared to the same period a year ago.
Amylyx Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2025-06-30 | - | 100.00% |
2025-03-31 | - | -100.00% |
2024-12-31 | $-665.00K | -259.86% |
2024-09-30 | $416.00K | -140.66% |
2024-06-30 | $-1.02M | -101.15% |
2024-03-31 | $88.64M | -18.26% |
2023-12-31 | $108.45M | 5.61% |
2023-09-30 | $102.69M | 4.56% |
2023-06-30 | $98.22M | 37.50% |
2023-03-31 | $71.43M | 226.38% |
2022-12-31 | $21.89M | 6243.48% |
2022-09-30 | $345.00K | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2021-09-30 | $285.00K | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $350.00K | - |
Amylyx Pharmaceuticals generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Amylyx Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
MAZE | Maze Therapeutics | $167.50M | - |
WVE | Wave Life Sciences | $108.30M | $8.70M |
AMLX | Amylyx Pharmaceuticals | $87.37M | - |
SNDX | Syndax Pharmaceuticals | $23.68M | $37.96M |
IMNM | Immunome | $9.04M | $2.93M |
NUVB | Nuvation Bio | $7.87M | $4.83M |
ATAI | Atai Life Sciences | - | $1.55M |
ELVN | Enliven Therapeutics | - | - |
PHVS | Pharvaris | - | - |
SYRE | Spyre Therapeutics | - | - |
ORIC | ORIC Pharmaceuticals | - | - |